Kennedy Capital Management Inc. acquired a new position in shares of Orthofix International N.V. (NASDAQ:OFIX) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 55,904 shares of the medical device company’s stock, valued at approximately $3,058,000. Kennedy Capital Management Inc. owned approximately 0.31% of Orthofix International at the end of the most recent reporting period.
A number of other institutional investors also recently added to or reduced their stakes in OFIX. Ramsey Quantitative Systems acquired a new position in Orthofix International during the fourth quarter worth $247,000. Crossmark Global Holdings Inc. bought a new stake in shares of Orthofix International during the fourth quarter worth $260,000. FineMark National Bank & Trust bought a new stake in shares of Orthofix International during the fourth quarter worth $266,000. Los Angeles Capital Management & Equity Research Inc. bought a new stake in shares of Orthofix International during the third quarter worth $315,000. Finally, Municipal Employees Retirement System of Michigan grew its holdings in shares of Orthofix International by 60.8% during the third quarter. Municipal Employees Retirement System of Michigan now owns 6,770 shares of the medical device company’s stock worth $320,000 after purchasing an additional 2,560 shares during the last quarter. Hedge funds and other institutional investors own 94.74% of the company’s stock.
Several analysts have recently commented on the company. BidaskClub upgraded Orthofix International from a “sell” rating to a “hold” rating in a report on Saturday, February 3rd. SunTrust Banks increased their target price on Orthofix International to $67.00 and gave the stock a “buy” rating in a report on Monday, March 5th. ValuEngine upgraded Orthofix International from a “hold” rating to a “buy” rating in a report on Thursday, March 1st. Finally, Gabelli restated a “buy” rating on shares of Orthofix International in a report on Wednesday, February 28th. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Orthofix International currently has an average rating of “Buy” and an average target price of $57.42.
Orthofix International (NASDAQ:OFIX) last posted its quarterly earnings results on Monday, February 26th. The medical device company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.50 by $0.02. The business had revenue of $116.90 million for the quarter, compared to analysts’ expectations of $116.93 million. Orthofix International had a return on equity of 10.66% and a net margin of 1.43%. The firm’s quarterly revenue was up 7.7% compared to the same quarter last year. During the same quarter last year, the business earned $0.42 earnings per share. equities analysts expect that Orthofix International N.V. will post 1.82 earnings per share for the current fiscal year.
WARNING: This report was first posted by American Banking News and is owned by of American Banking News. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://www.americanbankingnews.com/2018/03/14/kennedy-capital-management-inc-acquires-new-position-in-orthofix-international-n-v-ofix.html.
Orthofix International Profile
Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.
Receive News & Ratings for Orthofix International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix International and related companies with MarketBeat.com's FREE daily email newsletter.